title: [Studies on the multiple-drug induction immunosuppressive therapies with cyclosporine after renal transplantation].
abstract: Our induction immunosuppressive therapies were carried out on patients split into three groups. The first group of 25 recipients were treated with regimen I [cyclosporin (CsA); 12 mg/kg/day and prednisolone (Pred)]. The second group of 16 recipients were treated with regimen II [CsA; 6 mg/kg/day, Pred and mizoribine (MIZ) or azathioprine (AZA)]. The third group of 14 recipients were treated with regimen III [CsA; 10 mg/kg/day, Pred and MIZ or AZA]. There was no significant difference among the three groups in renal function three months after renal transplantation. The frequency and grade of rejection were significantly higher in Group II than in the other groups. One of group I had CsA nephrotoxicity and none of group III had liver dysfunction three months after renal transplantation. Group I had a higher incidence of posttransplant hypertension. Hypertension of group I was very severe. We concluded that the triple-drug therapy on group III was the best induction immunosuppressive therapy after renal transplantation of the above three.
authors.affiliation: Department of Urology, Kinki University School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Imanishi
authors.forename: M
authors.initials: M
authors.lastname: Negita
authors.forename: M
authors.initials: M
authors.lastname: Ikegami
authors.forename: T
authors.initials: T
authors.lastname: Nishioka
authors.forename: T
authors.initials: T
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Uemura
authors.forename: S
authors.initials: S
authors.lastname: Kunikata
authors.forename: H
authors.initials: H
authors.lastname: Kanda
authors.forename: T
authors.initials: T
authors.lastname: Matsuura
authors.forename: T
authors.initials: T
authors.lastname: Akiyama
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011239:Prednisolone / Q000008:administration & dosage; D012263:Ribonucleosides / Q000008:administration & dosage
chemical_list: D003524:Cyclosporins; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D011239:Prednisolone; D003404:Creatinine; D001379:Azathioprine